scholarly journals Structural and Biochemical Studies of the Hedamycin Type II Polyketide Ketoreductase (HedKR): Molecular Basis of Stereo- and Regiospecificities

Biochemistry ◽  
2011 ◽  
Vol 50 (34) ◽  
pp. 7426-7439 ◽  
Author(s):  
Pouya Javidpour ◽  
Abhirup Das ◽  
Chaitan Khosla ◽  
Shiou-Chuan Tsai
1998 ◽  
Vol 80 (09) ◽  
pp. 376-381 ◽  
Author(s):  
W. Lissens ◽  
S. Seneca ◽  
P. Capel ◽  
B. Chatelain ◽  
P. Meeus ◽  
...  

SummaryThe molecular basis of hereditary antithrombin (AT) deficiency has been investigated in ten Belgian and three Dutch unrelated kindreds. Eleven of these families had a quantitative or type I AT deficiency, with a history of major venous thromboembolic events in different affected members. In the other two families a qualitative or type II AT deficiency was occasionally diagnosed.DNA studies of the AT gene were performed, using polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) analysis, followed by direct sequencing of the seven exons and intronexon junction regions. Six novel point mutations were identified: four missense, one nonsense mutation and a single nucleotide deletion near the reactive site, causing a frameshift with premature translation termination. In two kindreds the underlying genetic defect was caused by a whole gene deletion, known as a rare cause of AT deficiency. In these cases, Southern blot and polymorphism analysis of different parts of the AT gene proved useful for diagnosis. In another kindred a partial gene deletion spanning 698 basepairs could precisely be determined to a part of intron 3B and exon 4. In two type I and in both type II AT deficient families a previously reported mutation was identified. In all cases, the affected individuals were heterozygous for the genetic defect.


Bone ◽  
1985 ◽  
Vol 6 (1) ◽  
pp. 55-56
Author(s):  
L.J. Fraher ◽  
G.N. Hendy ◽  
H. Jani ◽  
L. Nicholson ◽  
F.R.J. Hinde ◽  
...  

2010 ◽  
Vol 25 (9) ◽  
pp. 560-564 ◽  
Author(s):  
K J Carss ◽  
M Stowasser ◽  
R D Gordon ◽  
K M O'Shaughnessy

2018 ◽  
Vol 115 (33) ◽  
pp. E7748-E7757 ◽  
Author(s):  
Rami Khoriaty ◽  
Geoffrey G. Hesketh ◽  
Amélie Bernard ◽  
Angela C. Weyand ◽  
Dattatreya Mellacheruvu ◽  
...  

Approximately one-third of the mammalian proteome is transported from the endoplasmic reticulum-to-Golgi via COPII-coated vesicles. SEC23, a core component of coat protein-complex II (COPII), is encoded by two paralogous genes in vertebrates (Sec23a and Sec23b). In humans, SEC23B deficiency results in congenital dyserythropoietic anemia type-II (CDAII), while SEC23A deficiency results in a skeletal phenotype (with normal red blood cells). These distinct clinical disorders, together with previous biochemical studies, suggest unique functions for SEC23A and SEC23B. Here we show indistinguishable intracellular protein interactomes for human SEC23A and SEC23B, complementation of yeast Sec23 by both human and murine SEC23A/B, and rescue of the lethality of sec23b deficiency in zebrafish by a sec23a-expressing transgene. We next demonstrate that a Sec23a coding sequence inserted into the murine Sec23b locus completely rescues the lethal SEC23B-deficient pancreatic phenotype. We show that SEC23B is the predominantly expressed paralog in human bone marrow, but not in the mouse, with the reciprocal pattern observed in the pancreas. Taken together, these data demonstrate an equivalent function for SEC23A/B, with evolutionary shifts in the transcription program likely accounting for the distinct phenotypes of SEC23A/B deficiency within and across species, a paradigm potentially applicable to other sets of paralogous genes. These findings also suggest that enhanced erythroid expression of the normal SEC23A gene could offer an effective therapeutic approach for CDAII patients.


2019 ◽  
Vol 116 (41) ◽  
pp. 20404-20410 ◽  
Author(s):  
Amy J. Fernandez ◽  
Earnest James Paul Daniel ◽  
Sai Pooja Mahajan ◽  
Jeffrey J. Gray ◽  
Thomas A. Gerken ◽  
...  

Polypeptide N-acetylgalactosaminyl transferases (GalNAc-Ts) initiate mucin type O-glycosylation by catalyzing the transfer of N-acetylgalactosamine (GalNAc) to Ser or Thr on a protein substrate. Inactive and partially active variants of the isoenzyme GalNAc-T12 are present in subsets of patients with colorectal cancer, and several of these variants alter nonconserved residues with unknown functions. While previous biochemical studies have demonstrated that GalNAc-T12 selects for peptide and glycopeptide substrates through unique interactions with its catalytic and lectin domains, the molecular basis for this distinct substrate selectivity remains elusive. Here we examine the molecular basis of the activity and substrate selectivity of GalNAc-T12. The X-ray crystal structure of GalNAc-T12 in complex with a di-glycosylated peptide substrate reveals how a nonconserved GalNAc binding pocket in the GalNAc-T12 catalytic domain dictates its unique substrate selectivity. In addition, the structure provides insight into how colorectal cancer mutations disrupt the activity of GalNAc-T12 and illustrates how the rules dictating GalNAc-T12 function are distinct from those for other GalNAc-Ts.


1997 ◽  
Vol 15 (12) ◽  
pp. 1529-1530
Author(s):  
A Li ◽  
R Tedde ◽  
M Palermo ◽  
C H.L. Shackleton ◽  
P M. Stewart

2002 ◽  
Vol 161 (6) ◽  
pp. 2027-2034 ◽  
Author(s):  
Guido A. Hegasy ◽  
Tamara Manuelian ◽  
Kolbjorn Hogasen ◽  
Johan H. Jansen ◽  
Peter F. Zipfel

1999 ◽  
Vol 104 (1) ◽  
pp. 94-98 ◽  
Author(s):  
M. L. Huie ◽  
A. L. Shanske ◽  
J. S. Kasper ◽  
R. W. Marion ◽  
R. Hirschhorn

Sign in / Sign up

Export Citation Format

Share Document